mTORC1/SREBP2/cholesterol-mediated NKT dysfunction in the tumor-promoting NAFLD was proposed as one of the intervention strategies targeting NKT cells to control HCC development in NAFLD/NASH. This evidence concerns the gene SREBF2 and metabolic dysfunction-associated steatotic liver disease.